Amgen entered an agreement to acquire Five Prime Therapeutics for approximately $1.9 billion in cash. This acquisition adds Five Prime's innovative pipeline of immuno-oncology and targeted cancer therapies to Amgen's oncology portfolio.
Type 2 diabetes mellitus increases the risk for gastric cancer after treatment for Helicobacter pyloriinfection, according to a study published online in Diabetes Care.